In this issue of The Lancet Diabetes & Endocrinology, Michelle M Chen and colleagues1 report their findings on trends in the incidence of thyroid cancer in the USA from 1975 to 2019. The authors show ...

Several therapeutic advances have been achieved over the past two decades for inflammatory bowel disease (IBD). The expanding ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

All physicians are faced with the challenge of how to help patients with no approved therapies for their diseases. What are ...

Since the first, seminal randomised controlled trial (RCT) in inflammatory bowel disease (IBD) in 1955,1 the central tenets ...

Artificial intelligence (AI) for mammography is an early exemplar of the integration of AI systems into clinical pathways and ...

The global incidence of cancer reached 20 million in 2022 and is projected to rise to 33·1 million by 2050.1 Amid the growing ...

We read with interest the article by Marie Lund and colleagues published in The Lancet Oncology investigating the association ...

A 58-year-old male patient presented to the dermatology clinic at West China Hospital of Sichuan University (Chengdu, Sichuan ...

The phase 2 REST trial by Frida Bugge Askeland and colleagues, reported in The Lancet Haematology, provides insight into ...

Editorial, The Lancet Infectious Diseases discussed the over-reaching inferences leading to suggestions of a placental microbiome, and touched on how the same extrapolations were leading some to make ...

We would like to thank Nikolas Ruffer and Martin Krusche for their considered Correspondence; their letter raised an important point regarding the nomenclature used in our case report. The authors ...